CancerTyppeID
CancerTYPE ID is a proprietary molecular cancer classifier used to identify unknown or unclear tumor types and subtypes in patients with metastatic cancer. When ordered through NeoGenomics, classification with CancerTYPE ID is followed by tumor profiling for actionable biomarkers using the NeoTYPE® Cancer Profile most appropriate for the tumor type identified by Cancer TYPE ID.† Tech-only options for FISH and IHC within the NeoTYPE Cancer Profile are available.
CancerTYPE ID is performed and billed separately by NeoGenomics’ contracted reference laboratory, Biotheranostics, Inc., an independent CLIA-licensed and CAP-accredited reference laboratory. The test uses quantitative RT-PCR to measure the expression of 92 genes in the patient’s specimen and classifies the tumor by matching the gene expression profile to a database of more than 2000 known tumor types and subtypes.
Several recent studies demonstrated that the 92-gene assay affected diagnosis and treatment selection in a significant proportion of patients, which supports the clinical utility of the assay as a standardized molecular approach to help streamline additional diagnostic testing in patients with metastatic cancer with unknown or uncertain diagnoses. These
Newer studies cited below specifically support this test and conclude that it is clinically useful.
FINAL EXTERNAL REVIEW DECISION
Sachdev P. Thomas et al, Multi-Institutional, Prospective Clinical Utility Study Evaluating the Impact of the 92-Gene Assay (CancerTYPE ID) on Final Diagnosis and Treatment Planning in Patients With Metastatic Cancer With an Unknown or Unclear Diagnosis. DOI: 10.1200/PO.17.00145 JCO Precision Oncology – published online March 5, 2018 Nov. 2021
Wu F, Huang D, Wang L, Xu Q, Liu F, Ye X, Meng X, Du X. 92-Gene molecular profiling in identification of cancer origin: a retrospective study in Chinese population and performance within different subgroups. PLoS One. 2012;7(6):e39320.
Daruka Mahadevan et al, I. J ImmonotherNTEGRATIONOFMOLECULAR CANCER CLASSIFICATION AND NEXT-GENERATION SEQUENCING TO IDENTIFY METASTATIC PATIENTS ELIGIBLE FOR IMMUNE CHECKPOINT INHIBITORS. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://jitc.bmj.com/content/jitc/9/Suppl_2/A356.full.pdf
newer studies cited below specifically support this test and conclude that it is clinically useful.
Sachdev P. Thomas et al, Multi-Institutional, Prospective Clinical Utility Study Evaluating the Impact of the 92-Gene Assay (CancerTYPE ID) on Final Diagnosis and Treatment Planning in Patients With Metastatic Cancer With an Unknown or Unclear Diagnosis. DOI: 10.1200/PO.17.00145 JCO Precision Oncology – published online March 5, 2018 Nov. 2021
Wu F, Huang D, Wang L, Xu Q, Liu F, Ye X, Meng X, Du X. 92-Gene molecular profiling in identification of cancer origin: a retrospective study in Chinese population and performance within different subgroups. PLoS One. 2012;7(6):e39320.
Daruka Mahadevan et al, I. J ImmonotherNTEGRATIONOFMOLECULAR CANCER CLASSIFICATION AND NEXT-GENERATION SEQUENCING TO IDENTIFY METASTATIC PATIENTS ELIGIBLE FOR IMMUNE CHECKPOINT INHIBITORS. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://jitc.bmj.com/content/jitc/9/Suppl_2/A356.full.pdf